KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Sales and Divestitures: 2013-2024

  • Ionis Pharmaceuticals' Gains from Sales and Divestitures rose 12.32% to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 million, marking a year-over-year increase of 12.32%. This contributed to the annual value of $1.2 million for FY2024, which is 12.32% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Gains from Sales and Divestitures of $1.2 million as of Q4 2024, which was up 12.32% from $1.1 million recorded in Q4 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Gains from Sales and Divestitures peaked at $1.2 million during Q4 2024, and registered a low of $602,000 during Q4 2020.
  • For the 3-year period, Ionis Pharmaceuticals' Gains from Sales and Divestitures averaged around $1.1 million, with its median value being $1.1 million (2023).
  • Data for Ionis Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY soared of 42.65% (in 2020) over the last 5 years.
  • Over the past 5 years, Ionis Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $602,000 in 2020, then skyrocketed by 38.54% to $834,000 in 2021, then climbed by 14.87% to $958,000 in 2022, then grew by 10.13% to $1.1 million in 2023, then rose by 12.32% to $1.2 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.2 million for Q4 2024, versus $1.1 million for Q4 2023 and $958,000 for Q4 2022.